124 related articles for article (PubMed ID: 3493292)
1. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.
Shiohara T; Moellmann G; Jacobson K; Kuklinska E; Ruddle NH; Lerner AB
J Immunol; 1987 Mar; 138(6):1979-86. PubMed ID: 3493292
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. I. Destruction of B16 melanoma cells mediated by bystander cytolysis in vitro.
Shiohara T; Ruddle NH; Horowitz M; Moellmann GE; Lerner AB
J Immunol; 1987 Mar; 138(6):1971-8. PubMed ID: 3102609
[TBL] [Abstract][Full Text] [Related]
3. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
4. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
5. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
6. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
7. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
8. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
9. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
10. Activation of Lyt-1+ and Lyt-2+ T cell cloned lines: stimulation of proliferation, lymphokine production, and self-destruction.
Conta BS; Powell MB; Ruddle NH
J Immunol; 1985 Apr; 134(4):2185-90. PubMed ID: 2579131
[TBL] [Abstract][Full Text] [Related]
11. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
15. Activation of B cells by autoreactive T cells: cloned autoreactive T cells activate B cells by two distinct pathways.
Finnegan A; Needleman B; Hodes RJ
J Immunol; 1984 Jul; 133(1):78-85. PubMed ID: 6202794
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
17. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
18. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
19. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.
Nishihara K; Miyatake S; Sakata T; Yamashita J; Kikuchi H; Kawade Y; Zu Y; Namba Y; Hanaoka M; Watanabe Y
Cancer Res; 1988 Sep; 48(17):4730-5. PubMed ID: 3136912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
